Welcome to QBiotics

  • We are an unlisted Australian public company.
  • We discover, develop and commercialise novel anticancer and wound healing pharmaceuticals for human and veterinary markets.
  • Our lead drug, tigilanol tiglate, is a small molecule anticancer pharmaceutical targeting a range of solid tumours across multiple species.
  • The simultaneous development of products for both the vet and human markets enables validation of technology and reduces risks for human development, while generating early revenues.